|North American Banks Fund
||EPS - Basic
||Market Cap (m)
|Equity Investment Instruments
Real-Time news about North American (London Stock Exchange): 0 recent articles
|energyi: Last Updated: 10/23/2006
Exchange: TSX Venture
Current Share Price: $0.52
Shares Outstanding: 32.6 million
Shares Fully Diluted: 46.5 million
52 Week Range (Lo - Hi): $0.30 - 0.62
Market Capitalization: $16.952 million
SUBJECT: Toronto Resource Investment Conference Posted By: pyoing
Post Time: 9/25/2006 22:28
I attended the conference and listened to the Nam corporate presentation given by Tommy Cheng CEO.
Most of what Tommy spoke is already on their website, but there were a few additions that some may find useful.
- there will be a NI43-101 due out November.
- 2007: 10,000oz. gold to be poured, with an additional 5,000oz. from
newly acquired properties.
- US. OTC.BB listing is not being considered by NAM, but in the future
the company does want to graduate from the Frankfurt onto
Hong Kong exchange.
- over a $million in the kitty.
SUBJECT: RE: Toronto Resource Investment Conference Posted By: joemanner
Post Time: 9/25/2006 22:42
The conference is informative to me as they have some new exciting projects due to have news coming out soon.
I found out a new surge on projects on China after reading the Northern Miner issue on the China/ Mongolia. NAM is definitely among one of them as it has featured, not bad for a Company only listed for less than 6 months!
SUBJECT: RE: Toronto Resource Investment Conference Posted By: BillyMiner
Post Time: 9/28/2006 15:38
I spoke to the guys at the show as well.
NAM has poured 400 oz of gold already from the Majiahe Property and will most likely get about 2000 oz in total from that project this year. As Pyoing said, they will get another 10,000 oz next year. The newly acquired property will also have production. They have an amazing exploration property (Xuefeng Property) with huge potential and they are currently working on a 43-101 for it. I got the feeling that they are also looking at some other properties to acquire as well. This company has awesome potential for the short and long term.
|derek wild: Trouble seems to be nigh for Nycomed Amersham. The healthcare company's shares are on the slippery slope and, since closing at 700p early in July, they have lost 10pc. They finished at 629p, down 14p, yesterday, but CSFB reckons they should be trading at nearer 429p.
"The problem is the next year's Nasdaq listing of a 10pc stake in APBiotech, its life sciences venture with Pharmacia, of the US," says the Guardian. "Earlier this week, Nycomed filed registration documents for the float with the US regulators that forced it to disclose the previously unavailable divisional profitability of APB.
"After inspection of the documents, CSFB has concluded that APB is significantly less profitable than its closest rival, Applied Biosystems. CSFB reckons Nycomed's 45pc stake in APB is worth no more than 242p. Combined with the rest of the Nycomed operations, CSFB finds it hard to justify a share price higher than 443p and is advising its clients to sell."|
North American Banks Fund share price data is direct from the London Stock Exchange